A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.

Authors

Hope S. Rugo

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Hope S. Rugo , Peter Kabos , Joseph Thaddeus Beck , Michael Jon Chisamore , Anwar Hossain , Yanyun Chen , Sara M. Tolaney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.

First Author: Sara M. Tolaney

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.

First Author: Rachel M. Layman

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.

First Author: Elgene Lim

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

First Author: Erika P. Hamilton